Navigation Links
MIGENIX Reports Third Quarter Fiscal Year 2008 Financial Results
Date:3/13/2008

ted on MX-2401 have demonstrated very favorable activity with low toxicity, a long half-life, and other positive pharmacological and competitive features (with efficacy in multiple animal models, including pneumonia). Good Laboratory Practices ("GLP") compliant non-clinical studies were initiated in April 2007. Activities in the program are currently focused on manufacturing process development and advancing the program into the clinic in late 2009.

SB 9000 (dinucleotide; treatment of chronic hepatitis B virus infections): This preclinical program was out-licensed to Spring Bank Technologies and is supported in part with NIH funding. Spring Bank has made significant progress and plans to advance the program into the clinic in 2009. We have a convertible preferred share ownership position in Spring Bank.

MX-4565 (small molecule; treatment of neurodegenerative diseases): In June 2007 we were awarded a grant from the Michael J. Fox Foundation to fund research in our MX-4565 program. Studies funded by the grant are ongoing.

Other Matters: We provided notice to the University of Florida Research Foundation Inc. (UFRFI) of the termination of the license agreement between the Company and UFRFI. The license agreement relates primarily to the Company's MX-4509 program that was written off in the year ended April 30, 2007.

FINANCIAL RESULTS

For the three months ended January 31, 2008 ("Q3/08"), MIGENIX incurred a loss of $3.4 million (Q3/07: $6.7 million) or $0.04 (Q3/07: $0.08) per common share, and for the nine months ended January 31, 2008 ("YTD Fiscal 2008") the loss is $9.5 million ($0.10 per common share) compared to a loss of $12.9 million ($0.16 per common share) for the nine months ended January 31, 2007 ("YTD Fiscal 2007"). The YTD Fiscal 2008 loss includes $2.5 million in non-cash expenses (YTD Fiscal 2007: $5.5 million). The $3.3 million decrease in the Q3/08 loss compared to the Q3/07 loss is principally attributable to a $2.8 m
'/>"/>

SOURCE MIGENIX Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. MIGENIX Third Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
2. MIGENIX releases CEO message #22
3. MIGENIX to Add 600mg Daily Celgosivir Dose to Phase II Viral Kinetics Study
4. MIGENIX Reports Second Quarter Fiscal Year 2008 Financial Results
5. MIGENIX Second Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
6. MIGENIX to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
7. MIGENIX Reports First Quarter Fiscal Year 2008 Financial Results
8. MIGENIX to Present Positive Celgosivir Viral Resistance Data at International HCV Meeting
9. MIGENIX First Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
10. Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results
11. Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 30, 2015 AACC welcomed thousands of ... AACC Annual Meeting & Clinical Lab Expo in ... The meeting showcased revolutionary advancements in clinical testing ... healthcare providers to diagnose patients quickly and accurately ... As of Wednesday, July 29, ...
(Date:7/30/2015)... ... ... The 2015 Market Research Report on the Global Propanol Industry is ... with a focus on the Chinese situation. Major companies included in the propanol market ... Royal Dutch Shell, LG Chem and Zhejiang Xinhua Chemical. , The report provides a ...
(Date:7/30/2015)... Kan. , July 30, 2015   ... a pet therapeutics company focused on the licensing, ... companion animals, today announced that its strategic partner ... a dose confirmation study of AT-016, an adipose-derived ... for the treatment of osteoarthritis pain in dogs. ...
(Date:7/30/2015)... COPENHAGEN, Denmark , July 30, 2015 /PRNewswire/ ... a biotechnology company that applies its innovative TransCon ... announced positive top-line results from a six-month Phase ... of once-weekly TransCon Growth Hormone in 53 treatment-naïve, ... "We are extremely pleased with the ...
Breaking Biology Technology:Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 3Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 4Global Propanol Market Technical Data and Manufacturing Analysis 2020 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7
... AMES, Iowa - Researchers at the U.S. Department ... a potentially perfect way to sort and distribute ... over optical fibers to people ,throughout the world. ... filter, promises greatly enhanced transmission of multiple ,wavelength ...
... Feb. 18 - Biotech pioneer,William J. Rutter, PhD, ... RAPS,Horizons Conference & Exhibition in San Francisco next ... Rutter, Chairman and CEO of Synergenics LLC ... fresh and relevant perspectives on,the regulatory implications of ...
... 18 JADO Technologies GmbH,the leading developer of ... Phase IIa clinical trial of its lead RAFT ... a topical,formulation of miltefosine, exerts its anti- inflammatory ... lipid membrane of cells that,play a role in ...
Cached Biology Technology:New filter clears up fiber optic communications 2New filter clears up fiber optic communications 3Biotech Pioneer William J. Rutter to Deliver Keynote at 2008 RAPS Horizons Conference 2JADO Reports Clinical Proof of Concept With Raft Modulator in Atopic Dermatitis 2JADO Reports Clinical Proof of Concept With Raft Modulator in Atopic Dermatitis 3
(Date:7/27/2015)...   Zynx Health ™, the market leader ... today announced that its ZynxCarebook ™ mobile ... smartphones and tablets. With this expansion, care team ... ZynxCarebook to securely exchange messages and share assessments ... to other care settings, and improve clinical outcomes ...
(Date:7/21/2015)... -- Today, ZTE announced its Android smartphone Axon, featuring ... revenues in 2015 that relate to sales of FPC1025 for this ... 2,200 MSEK for 2015. Jörgen Lantto, CEO of FPC, ... China and we are proud that ... Axon , its first ...
(Date:7/20/2015)... , July 20, 2015  Acuity Market ... Report: The Convergence of Commerce and Privacy" forecasts ... mobile biometric apps will be downloaded to smart ... The mobile biometrics market is projected to generate ... revenue during the seven-year forecast period.    ...
Breaking Biology News(10 mins):Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3FPC's Touch Fingerprint Sensor FPC1025 in ZTE's Smartphone Axon 2Biometrics on Smart Mobile Devices to Redefine Digital Identity with 12.9 Billion Biometric App Downloads between 2014 and 2020 2
... science takes a giant leap forward with a new ... new $1.5 million per year Pedo-Biometrics Research and Identity ... Ottawa, Canada, company currently relocating operations to the U.S., ... of identification uses, from security to detecting the onset ...
... Santa Barbara, Calif. As spatial planning is used increasingly ... to determine the best ways to use and refine the ... (MPAs), one of the most common methods, which limit or ... paper published in the early edition of the Proceedings ...
... Technology (Caltech) pioneered the study of the link ... disorders such as autism a decade ago. Since ... with autism, as well as epidemiological studies, have ... system and autism spectrum disorder. What has ...
Cached Biology News:Carnegie Mellon University's Biometrics Center Selected To House New Pedo-Biometrics Research and Identity Automation Lab 2Carnegie Mellon University's Biometrics Center Selected To House New Pedo-Biometrics Research and Identity Automation Lab 3Refining the tool kit for sustainable fisheries 2Refining the tool kit for sustainable fisheries 3Caltech researchers find evidence of link between immune irregularities and autism 2Caltech researchers find evidence of link between immune irregularities and autism 3
...
...
... Transfer Vector is a derivative of the pAcHLT-A ... blue fluorescent protein (BFP), followed by a 6xHis ... are expressed as BFP-6xHis fusion proteins when cloned ... I, Stu I, Sac I, Not I, Pst ...
Mouse monoclonal antibody to PDK2 - pyruvate dehydrogenase kinase, isoenzyme 2...
Biology Products: